- - - - - - - Thoracoabdominal aorta;1;18
- - - - - - Vaccine;2;18
- - - - - Alpha-adrenoreceptor antagonists;3;18
- - - - - Aminoglycosides;4;18
- - - - - Aminophylline, theophylline;5;18
- - - - - Androgens and anabolic congeners;6;18
- - - - - Angiotensin-converting-enzyme inhibitors;7;18
- - - - - Anterior pituitary [adenohypophyseal] hormones;8;18
- - - - - Anthelminthics;9;18
- - - - - Antiallergic and antiemetic drugs;10;18
- - - - - Antiasthmatics, not elsewhere classified;11;18
- - - - - Anticholinesterase agents;12;18
- - - - - Anticoagulant antagonists, vitamin K and other coagulants;13;18
- - - - - Anticoagulants;14;18
- - - - - Antidiarrhoeal drugs;15;18
- - - - - Antidotes and chelating agents, not elsewhere classified;16;18
- - - - - Antifungal antibiotics, systemically used;17;18
- - - - - Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified;18;18
- - - - - Antihyperlipidemic and antiarteriosclerotic drugs;19;18
- - - - - Antimalarials and drugs acting on other blood protozoa;20;18
- - - - - Antimycobacterial drugs;21;18
- - - - - Antineoplastic antimetabolites;22;18
- - - - - Antineoplastic natural products;23;18
- - - - - Antipruritics;24;18
- - - - - Antithrombotic drugs [platelet aggregation inhibitors];25;18
- - - - - Antithyroid drugs;26;18
- - - - - Antitussives;27;18
- - - - - Antivaricose drugs, including sclerosing agents;28;18
- - - - - Antivenin, antivenom (sera), Immunoglobulin;29;18
- - - - - Antiviral drugs;30;18
- - - - - Appetite depressants;31;18
- - - - - Benzothiadiazine derivatives [thiazides];32;18
- - - - - Beta-adrenoreceptor antagonists;33;18
- - - - - Bromine compounds;34;18
- - - - - Calcium-channel ers;35;18
- - - - - Camphor;36;18
- - - - - Carbonic-anhydrase inhibitors;37;18
- - - - - Cardiac-stimulant glycosides and drugs of similar action;38;18
- - - - - Centrally-acting and adrenergic-neuron-ing agents;39;18
- - - - - Cephalosporins and other beta-lactam antibiotics;40;18
- - - - - Chloramphenicol group;41;18
- - - - - Cloral derivatives;42;18
- - - - - Digestants;43;18
- - - - - Drugs affecting uric acid metabolism;44;18
- - - - - Electrolytic, caloric and water-balance agents;45;18
- - - - - Emetics;46;18
- - - - - Emollients, demulcents and protectants;47;18
- - - - - Expectorants;48;18
- - - - - Fluoride preparations;49;18
- - - - - Ganglionic ing drugs;50;18
- - - - - Glucocorticoids and synthetic analogues;51;18
- - - - - Histamine H2-receptor ers;52;18
- - - - - Immunosuppressive agents;53;18
- - - - - Insulin and oral hypoglycemic [antidiabetic] drugs;54;18
- - - - - Intravenous anesthetics;55;18
- - - - - Iodine (antiseptic);56;18
- - - - - Iron and its compounds;57;18
- - - - - Keratolytics, keratoplastics, and other hair treatment drugs and preparations;58;18
- - - - - Local anesthetics;59;18
- - - - - Loop [high-ceiling] diuretics;60;18
- - - - - Macrolides;61;18
- - - - - Methyl salicylate;62;18
- - - - - Mineral salts, not elsewhere classified;63;18
- - - - - Mineralocorticoids;64;18
- - - - - Mineralocorticoids antagonists;65;18
- - - - - Mixed sedatives and hypnotics, not elsewhere classified;66;18
- - - - - Natural blood and blood products;67;18
- - - - - Nitroglycerin, nitroglycerol (medicinal);68;18
- - - - - Ophthalmological drugs and preparations;69;18
- - - - - Oral contraceptives;70;18
- - - - - Other agents primarily affecting the cardiovascular system;71;18
- - - - - Other and unspecified primarily systemic and haematological agent;72;18
- - - - - Other antacids and anti-gastric-secretion drugs;73;18
- - - - - Other anti-common-cold drugs;74;18
- - - - - Other antidysrhythmic drugs;75;18
- - - - - Other antihypertensive drugs;76;18
- - - - - Other antineoplastic drugs;77;18
- - - - - Other antiprotozoal drugs;78;18
- - - - - Other coronary vasodilators;79;18
- - - - - Other dental drugs, topically applied;80;18
- - - - - Other diagnostic agents;81;18
- - - - - Other diuretics;82;18
- - - - - Other drug primarily affecting the autonomic nervous system;83;18
- - - - - Other drugs acting on muscles;84;18
- - - - - Other drugs and medicaments;85;18
- - - - - Other estrogens and progestogens;86;18
- - - - - Other fibrinolysis-affecting drugs;87;18
- - - - - Other H1-receptor antagonists;88;18
- - - - - Other hormones and synthetic substitutes;89;18
- - - - - Other inhaled anesthetics;90;18
- - - - - Other laxatives;91;18
- - - - - Other local antifungal, anti-infective and anti-inflammatory drugs;92;18
- - - - - Other local astringents and local detergents;93;18
- - - - - Other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics;94;18
- - - - - Other parasympathomimetics [cholinergics];95;18
- - - - - Other sedatives, hypnotics and antianxiety drugs;96;18
- - - - - Other specified general anaesthetic;97;18
- - - - - Other specified systemic anti-infectives and antiparasitics;98;18
- - - - - Other systemic antibiotics;99;18
- - - - - Other topical agents;100;18
- - - - - Otorhinolaryngological drugs and preparations;101;18
- - - - - Oxytocic drugs;102;18
- - - - - Paraldehyde;103;18
- - - - - Penicillins;104;18
- - - - - Peripheral vasodilators;105;18
- - - - - Plasma substitutes;106;18
- - - - - Podophyllin;107;18
- - - - - Predominantly alpha-adrenoreceptor agonists;108;18
- - - - - Predominantly beta-adrenoreceptor agonists;109;18
- - - - - Rifampicins;110;18
- - - - - Saline and osmotic laxatives;111;18
- - - - - Silver nitrate;112;18
- - - - - Skeletal muscle relaxants [neuromuscular ing agents];113;18
- - - - - Stimulant laxatives;114;18
- - - - - Sulfonamides;115;18
- - - - - Tetracyclines;116;18
- - - - - Therapeutic gases;117;18
- - - - - Thrombolytic drug;118;18
- - - - - Thyroid hormones and substitutes;119;18
- - - - - Topical corticosteroid preparations;120;18
- - - - - Unspecified agents primarily affecting the gastrointestinal system;121;18
- - - - - Unspecified anesthetic;122;18
- - - - - Unspecified general anesthetics;123;18
- - - - - Unspecified systemic anti-infective and antiparasitics;124;18
- - - - - Unspecified topical agent;125;18
- - - - - Vitamin B12, folic acid and other anti-megaloblastic-anaemia preparations;126;18
- - - - - Vitamins, not elsewhere classified;127;18
- - - - - X-ray contrast media;128;18
- - - - 4-Aminophenol derivatives;129;18
- - - - Agents primarily acting on smooth and skeletal muscles and the respiratory system;130;18
- - - - Agents primarily affecting blood constituents;131;18
- - - - Agents primarily affecting the cardiovascular system;132;18
- - - - Agents primarily affecting the gastrointestinal system;133;18
- - - - Agents primarily affecting water-balance and mineral and uric acid metabolism;134;18
- - - - Anaesthetics and therapeutic gases;135;18
- - - - Analeptics;136;18
- - - - Antiparkinsonism drugs and other central muscle-tone depressants, not elsewhere classified;137;18
- - - - Antirheumatics, not elsewhere classified;138;18
- - - - Antispasticity drugs;139;18
- - - - Aspirin;140;18
- - - - Butyrophenone and thiothixene neuroleptics;141;18
"- - - - Cathinone (main active agent in Khat; benzoylethanamine)";142;18
- - - - Contact allergens in clothing or footwear;143;18
- - - - Contact allergens in cosmetics;144;18
- - - - Contact allergens in dental materials;145;18
- - - - Contact allergens in food flavours or additives;146;18
- - - - Contact allergens in fragrances;147;18
- - - - Contact allergens in hairdressing products;148;18
- - - - Contact allergens in industrial biocides, cutting oils or disinfectants;149;18
- - - - Contact allergens in metals or metal salts;150;18
- - - - Contact allergens in plants or other organic matter;151;18
- - - - Contact allergens in plastics, glues or resin systems;152;18
- - - - Contact allergens in preservatives or biocides;153;18
- - - - Contact allergens in rubber chemicals;154;18
- - - - Contact allergens in systemic medicaments;155;18
- - - - Contact allergens in topical medicaments;156;18
- - - - Deoxybarbiturates;157;18
- - - - Drugs primarily affecting the autonomic nervous system;158;18
- - - - Hormones and their synthetic substitutes and antagonists, not elsewhere classified;159;18
- - - - Hydantoin derivatives;160;18
- - - - Iminostilbenes;161;18
- - - - Lithium carbonate;162;18
- - - - Lymphatic system;163;18
- - - - Methylenedioxy methamphetamine [MDMA, Ecstasy];164;18
- - - - Methylphenidate;165;18
- - - - Mixed antiepileptics, not elsewhere classified;166;18
- - - - Monoamine-oxidase-inhibitor antidepressants;167;18
- - - - Opioid receptor antagonists;168;18
- - - - Opioids or related analgesics;169;18
- - - - Other and unspecified drugs, medicaments and biological substances;170;18
- - - - Other antidepressants;171;18
- - - - Other antipsychotics and neuroleptics;172;18
- - - - Other nonopioid analgesics and antipyretics, not elsewhere classified;173;18
- - - - Other nonsteroidal anti-inflammatory drugs [NSAID];174;18
- - - - Other psychodysleptics [hallucinogens];175;18
- - - - Other psychotropic drugs;176;18
- - - - Other salicylates;177;18
- - - - Other specified amphetamines;178;18
- - - - Other systemic anti-infectives and antiparasitics;179;18
- - - - Oxazolidinediones;180;18
- - - - Paracetamol (acetaminophen);181;18
- - - - Phenothiazine antipsychotics and neuroleptics;182;18
- - - - Photoallergens in fragrances;183;18
- - - - Photoallergens in medicaments;184;18
- - - - Photoallergens in plants or vegetable matter;185;18
- - - - Photoallergens in preservatives or biocides;186;18
- - - - Photoallergens in sunscreens;187;18
- - - - Protein allergens;188;18
- - - - Pyrazolone derivatives;189;18
- - - - Sedative-hypnotic drugs;190;18
- - - - Selective serotonin and norepinephrine reuptake inhibitors;191;18
- - - - Selective serotonin reuptake inhibitors;192;18
- - - - Succinimides;193;18
- - - - Synthetic cannabinoids;194;18
- - - - Systemic antibiotics;195;18
- - - - Tendons;196;18
- - - - Tetracyclic antidepressants;197;18
- - - - Topical agents primarily affecting skin and mucous membrane and ophthalmological, otorhinolaryngological and dental drugs;198;18
- - - - Tricyclic antidepressants;199;18
- - - - Unspecified antidepressant drugss;200;18
- - - - Unspecified antiepileptic and antiparkinson drugs;201;18
- - - - Unspecified nonopioid analgesic, antipyretic and antirheumatic;202;18
- - - - Unspecified psychodysleptics [hallucinogens];203;18
- - - - Unspecified psychostimulant drug;204;18
- - - - Unspecified psychotropic drug;205;18
- - - Acinar cell neoplasms, benign;206;18
- - - Acinar cell neoplasms, malignant;207;18
- - - Acinar cell neoplasms, uncertain whether benign or malignant;208;18
- - - Adenomas and adenocarcinomas, benign;209;18
- - - Adenomas and adenocarcinomas, in situ;210;18
- - - Adenomas and adenocarcinomas, malignant;211;18
- - - Adenomas and adenocarcinomas, uncertain whether benign or malignant;212;18
- - - Adnexal and skin appendage neoplasms, benign;213;18
- - - Adnexal and skin appendage neoplasms, malignant;214;18
- - - Adnexal and skin appendage neoplasms, uncertain whether benign or malignant;215;18
- - - Analgesics, antipyretics and anti-inflammatory drugs;216;18
- - - Antidepressants;217;18
- - - Antiepileptics and antiparkinsonism drugs;218;18
- - - Antipsychotics [neuroleptics];219;18
- - - Auditory system;220;18
- - - Bacteria;221;18
- - - Basal cell neoplasms, benign;222;18
- - - Basal cell neoplasms, malignant;223;18
- - - Basal cell neoplasms, uncertain whether benign or malignant;224;18
- - - Blood vessel tumours, benign;225;18
- - - Blood vessel tumours, malignant;226;18
- - - Blood vessel tumours, uncertain whether benign or malignant;227;18
- - - Body Cavities;228;18
- - - Body Organ;229;18
- - - Body Tissues;230;18
- - - Cannabinoids & hallucinogens;231;18
- - - Carbon monoxide;232;18
- - - Chronic myeloproliferative disorders, malignant;233;18
- - - Circulatory system;234;18
- - - Complex epithelial neoplasms, benign;235;18
- - - Complex epithelial neoplasms, malignant;236;18
- - - Complex mixed and stromal neoplasms, benign;237;18
- - - Complex mixed and stromal neoplasms, malignant;238;18
- - - Complex mixed and stromal neoplasms, uncertain whether benign or malignant;239;18
- - - Context of assault and maltreatment;240;18
- - - Corrosive substance;241;18
- - - Counterpart in land transport crash;242;18
- - - Course;243;18
- - - Cystic, mucinous and serous neoplasms, benign;244;18
- - - Cystic, mucinous and serous neoplasms, in situ;245;18
- - - Cystic, mucinous and serous neoplasms, malignant;246;18
- - - Cystic, mucinous and serous neoplasms, uncertain whether benign or malignant;247;18
- - - Digestive system;248;18
- - - Ductal and lobular neoplasms, benign;249;18
- - - Ductal and lobular neoplasms, in situ;250;18
- - - Ductal and lobular neoplasms, malignant;251;18
- - - Economic activity;252;18
- - - Endocrine system;253;18
- - - Environmental countermeasures in sport or exercise;254;18
- - - Epithelial neoplasms, benign;255;18
- - - Epithelial neoplasms, in situ;256;18
- - - Epithelial neoplasms, malignant;257;18
- - - Epithelial neoplasms, uncertain whether benign or malignant;258;18
- - - Fibroepithelial neoplasms, benign;259;18
- - - Fibroepithelial neoplasms, malignant;260;18
- - - Fibroepithelial neoplasms, uncertain whether benign or malignant;261;18
- - - Fibromatous neoplasms, benign;262;18
- - - Fibromatous neoplasms, malignant;263;18
- - - Fibromatous neoplasms, uncertain whether benign or malignant;264;18
- - - Fungi;265;18
- - - Gender of perpetrator;266;18
- - - Genitourinary system;267;18
- - - Germ cell neoplasms, benign;268;18
- - - Germ cell neoplasms, in situ;269;18
- - - Germ cell neoplasms, malignant;270;18
- - - Germ cell neoplasms, uncertain whether benign or malignant;271;18
- - - Giant cell tumours, benign;272;18
- - - Giant cell tumours, malignant;273;18
- - - Gliomas, benign;274;18
- - - Gliomas, malignant;275;18
- - - Gliomas, uncertain whether benign or malignant;276;18
- - - Granular cell tumours and alveolar soft part sarcomas, benign;277;18
- - - Granular cell tumours and alveolar soft part sarcomas, malignant;278;18
- - - Haematopoietic system;279;18
- - - Halogen derivatives of aliphatic and aromatic hydrocarbons;280;18
- - - Helminths;281;18
- - - High molecular weight allergens;282;18
- - - Immune system;283;18
- - - Immunoproliferative diseases, malignant;284;18
- - - Immunoproliferative diseases, uncertain whether benign or malignant;285;18
- - - Integumentary system;286;18
- - - leukaemias, NOS, malignant;287;18
- - - Lice & Mites;288;18
- - - Lipomatous neoplasms, benign;289;18
- - - Lipomatous neoplasms, malignant;290;18
- - - Lipomatous neoplasms, uncertain whether benign or malignant;291;18
- - - Low molecular weight haptens;292;18
- - - Low molecular weight photohaptens;293;18
- - - Lymphatic vessel tumours, benign;294;18
- - - Lymphatic vessel tumours, malignant;295;18
- - - Lymphatic vessel tumours, uncertain whether benign or malignant;296;18
- - - Lymphoid leukaemias, malignant;297;18
- - - Mast cell tumours, malignant;298;18
- - - Mast cell tumours, uncertain whether benign or malignant;299;18
- - - Meningiomas, benign;300;18
- - - Meningiomas, malignant;301;18
- - - Meningiomas, uncertain whether benign or malignant;302;18
- - - Mesonephromas, benign;303;18
- - - Mesonephromas, malignant;304;18
- - - Mesonephromas, uncertain whether benign or malignant;305;18
- - - Mesothelial neoplasms, benign;306;18
- - - Mesothelial neoplasms, malignant;307;18
- - - Mesothelial neoplasms, uncertain whether benign or malignant;308;18
- - - Miscellaneous bone tumours, benign;309;18
- - - Miscellaneous bone tumours, malignant;310;18
- - - Miscellaneous tumours, benign;311;18
- - - Miscellaneous tumours, malignant;312;18
- - - Miscellaneous tumours, uncertain whether benign or malignant;313;18
- - - Mode of transport of person injured in transport event;314;18
- - - Mucoepidermoid neoplasms, malignant;315;18
- - - Mucoepidermoid neoplasms, uncertain whether benign or malignant;316;18
- - - Musculoskeletal system;317;18
- - - Myelodysplastic syndromes, malignant;318;18
- - - Myeloid leukaemias, malignant;319;18
- - - Myeloid leukaemias, uncertain whether benign or malignant;320;18
- - - Myomatous neoplasms, benign;321;18
- - - Myomatous neoplasms, malignant;322;18
- - - Myomatous neoplasms, uncertain whether benign or malignant;323;18
- - - Myxomatous neoplasms, benign;324;18
- - - Myxomatous neoplasms, malignant;325;18
- - - Neoplasms of histiocytes and accessory lymphoid cells, malignant;326;18
- - - Neoplasms of histiocytes and accessory lymphoid cells, uncertain whether benign or malignant;327;18
- - - Nerve sheath tumours, benign;328;18
- - - Nerve sheath tumours, malignant;329;18
- - - Nerve sheath tumours, uncertain whether benign or malignant;330;18
- - - Nervous system;331;18
- - - Neuroepitheliomatous neoplasms, benign;332;18
- - - Neuroepitheliomatous neoplasms, malignant;333;18
- - - Neuroepitheliomatous neoplasms, uncertain whether benign or malignant;334;18
- - - Nevi and melanomas, benign;335;18
- - - Nevi and melanomas, in situ;336;18
- - - Nevi and melanomas, malignant;337;18
- - - Nevi and melanomas, uncertain whether benign or malignant;338;18
- - - Non-hodgkin lymphomas;339;18
- - - Occupation;340;18
- - - Odontogenic tumours, benign;341;18
- - - Odontogenic tumours, malignant;342;18
- - - Onset;343;18
- - - Opioids;344;18
- - - Organic solvent;345;18
- - - Osseous and chondromatous neoplasms, benign;346;18
- - - Osseous and chondromatous neoplasms, malignant;347;18
- - - Osseous and chondromatous neoplasms, uncertain whether benign or malignant;348;18
- - - Other drugs;349;18
- - - Other haematologic disorders, malignant;350;18
- - - Other haematologic disorders, uncertain whether benign or malignant;351;18
- - - Other Infectious Agents;352;18
- - - Other leukaemias, malignant;353;18
- - - Other mechanisms of transport injury without counterpart;354;18
- - - Other Parasites;355;18
- - - Other substances;356;18
- - - Paragangliomas and glomus tumours, benign;357;18
- - - Paragangliomas and glomus tumours, malignant;358;18
- - - Paragangliomas and glomus tumours, uncertain whether benign or malignant;359;18
- - - Part of place;360;18
- - - Pattern, Activity, or Clinical Status;361;18
- - - Perperator-victim relationship;362;18
- - - Personal countermeasures in sport or exercise;363;18
- - - Pesticide;364;18
- - - Phase of sport or exercise activity;365;18
- - - Previous non-fatal intentional self harm;366;18
- - - Protozoa;367;18
- - - Proximal risk-factors for intentional self-harm;368;18
- - - Psychostimulants;369;18
- - - Respiratory system;370;18
- - - Role of injured person in armed conflict;371;18
- - - Sedative hypnotic drugs & other CNS depressants;372;18
- - - Soft tissue tumours and sarcomas, NOS, benign;373;18
- - - Soft tissue tumours and sarcomas, NOS, uncertain whether benign or malignant;374;18
- - - Specialized gonadal neoplasms, benign;375;18
- - - Specialized gonadal neoplasms, malignant;376;18
- - - Specialized gonadal neoplasms, uncertain whether benign or malignant;377;18
- - - Squamous cell neoplasms, benign;378;18
- - - Squamous cell neoplasms, in situ;379;18
- - - Squamous cell neoplasms, malignant;380;18
- - - Synovial-like neoplasms, benign;381;18
- - - Synovial-like neoplasms, malignant;382;18
- - - Thymic epithelial neoplasms, benign;383;18
- - - Thymic epithelial neoplasms, malignant;384;18
- - - Thymic epithelial neoplasms, uncertain whether benign or malignant;385;18
- - - Transitional cell papillomas and carcinomas, benign;386;18
- - - Transitional cell papillomas and carcinomas, in situ;387;18
- - - Transitional cell papillomas and carcinomas, malignant;388;18
- - - Transitional cell papillomas and carcinomas, uncertain whether benign or malignant;389;18
- - - Trophoblastic neoplasms, benign;390;18
- - - Trophoblastic neoplasms, malignant;391;18
- - - Trophoblastic neoplasms, uncertain whether benign or malignant;392;18
- - - Type of armed conflict;393;18
- - - Type of place;394;18
- - - Type of sport or exercise activity;395;18
- - - Vehicle user role of person injured in transport event;396;18
- - - Virus;397;18
- - - Visual system;398;18
- - - Walls in the Body;399;18
- - Acinar cell neoplasms;400;18
- - Activity when injured;401;18
- - Additional aspects of mechanism;402;18
- - Adenomas and adenocarcinomas;403;18
- - Adnexal and skin appendage neoplasms;404;18
- - Alcohol use in injury event;405;18
- - Allergens;406;18
- - Aspects of armed conflict;407;18
- - Aspects of assault and maltreatment;408;18
- - Aspects of intentional self-harm events;409;18
- - Aspects of occupational injury events;410;18
- - Aspects of place of injury occurrence;411;18
- - Aspects of sports injury events;412;18
- - Aspects of transport injury events;413;18
- - Assistive Devices;414;18
- - Basal cell neoplasms;415;18
- - Blood vessel tumours;416;18
- - Causality;417;18
- - Chemicals;418;18
- - Chronic myeloproliferative disorders;419;18
- - Clinical Staging Scale Value;420;18
- - Complex epithelial neoplasms;421;18
- - Complex mixed and stromal neoplasms;422;18
- - Course of the Condition;423;18
- - Cystic, mucinous and serous neoplasms;424;18
- - Diagnosis certainty;425;18
- - Diagnosis method of confirmation;426;18
- - Diagnosis timing;427;18
- - Diagnosis timing in relation to surgical procedure;428;18
- - Dimensions of Burns;429;18
- - Discharge diagnosis types;430;18
- - Distribution;431;18
- - Ductal and lobular neoplasms;432;18
- - Duration of pregnancy;433;18
- - Epithelial neoplasms, NOS;434;18
- - Fibroepithelial neoplasms;435;18
- - Fibromatous neoplasms;436;18
- - Fracture types;437;18
- - Functional anatomy;438;18
- - GCS Eye opening score;439;18
- - GCS Motor score;440;18
- - GCS Verbal score;441;18
- - Germ cell neoplasms;442;18
- - Giant cell tumours;443;18
- - Gliomas;444;18
- - Grading Scale Value;445;18
- - Granular cell tumours and alveolar soft part sarcomas;446;18
- - Histological Grading Scale Value;447;18
- - Hodgkin and non-Hodgkin lymphomas;448;18
- - Immunoproliferative diseases;449;18
- - Infectious Agents;450;18
- - Joint involvement in fracture;451;18
- - Laterality;452;18
- - Leukaemias;453;18
- - Lipomatous neoplasms;454;18
- - Lymphatic vessel tumours;455;18
- - Mast cell tumours;456;18
- - Medical Devices;457;18
- - Medicaments;458;18
- - Meningiomas;459;18
- - Mesonephromas;460;18
- - Mesothelial neoplasms;461;18
- - Mild Moderate Severe Scale Value;462;18
- - Miscellaneous bone tumours;463;18
- - Miscellaneous tumours;464;18
- - Mucoepidermoid neoplasms;465;18
- - Myelodysplastic syndromes;466;18
- - Myomatous neoplasms;467;18
- - Myxomatous neoplasms;468;18
- - Neoplasms of histiocytes and accessory lymphoid cells;469;18
- - Nerve sheath tumours;470;18
- - Neuroepitheliomatous neoplasms;471;18
- - Nevi and melanomas;472;18
- - Objects or living things involved in causing injury;473;18
- - Obstetrical diagnosis timing;474;18
- - Odontogenic tumours;475;18
- - Osseous and chondromatous neoplasms;476;18
- - Other haematologic disorders;477;18
- - Paragangliomas and glomus tumours;478;18
- - Partonomic view;479;18
- - Phase Scale Value;480;18
- - Plasma cell tumours;481;18
- - Problem Scale Value;482;18
- - Psychoactive drug use in injury event;483;18
- - Pupil reaction score;484;18
- - Regional;485;18
- - Relational;486;18
- - Soft tissue tumours and sarcomas, NOS;487;18
- - Specialized gonadal neoplasms;488;18
- - Squamous cell neoplasms;489;18
- - Surface topography;490;18
- - Synovial-like neoplasms;491;18
- - Thymic epithelial neoplasms;492;18
- - Time in Life;493;18
- - Transitional cell papillomas and carcinomas;494;18
- - Trophoblastic neoplasms;495;18
- - Tumor spread staging scale value;496;18
- - Tumour spread simplified scale value;497;18
- - Type of legal intervention;498;18
- - Types of superficial injuries;499;18
- - Whether fracture is open or closed;500;18
- Capacity or context;501;18
L1-1B7- Pyogenic bacterial infections of the skin or subcutaneous tissues;502;2
L1-1B9- Certain zoonotic bacterial diseases;503;2
L1-1C1- Other bacterial diseases;504;2
L1-1C6- Human immunodeficiency virus disease;505;2
L1-1C8- Viral infections of the central nervous system;506;2
L1-1D0- Non-viral and unspecified infections of the central nervous system;507;2
L1-1D2- Dengue;508;2
L1-1D4- Certain arthropod-borne viral fevers;509;2
L1-1D6- Certain zoonotic viral diseases;510;2
L1-1D8- Certain other viral diseases;511;2
L1-1E3- Influenza;512;2
L1-1E5- Viral hepatitis;513;2
L1-1F2- Mycoses;514;2
L1-1G4- Sepsis;515;2
L1-1G8- Sequelae of infectious diseases;516;2
L1-2A0- Neoplasms of brain or central nervous system;517;23
L1-2E6- In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues;518;23
L1-2F7- Neoplasms of uncertain behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues;519;23
L1-2F9- Neoplasms of unknown behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues;520;23
L1-3B8- Diseases of spleen;521;6
L1-4A0- Primary immunodeficiencies;522;11
L1-4A4- Nonorgan specific systemic autoimmune disorders;523;11
L1-4A6- Autoinflammatory disorders;524;11
L1-4A8- Allergic or hypersensitivity conditions;525;11
L1-4B0- Immune system disorders involving white cell lineages;526;11
L1-4B2- Certain disorders involving the immune system;527;11
L1-5D4- Postprocedural endocrine or metabolic disorders;528;17
L1-6A0- Neurodevelopmental disorders;529;22
L1-6A2- Schizophrenia or other primary psychotic disorders;530;22
L1-6A4- Catatonia;531;22
L1-6B0- Anxiety or fear-related disorders;532;22
L1-6B2- Obsessive-compulsive or related disorders;533;22
L1-6B4- Disorders specifically associated with stress;534;22
L1-6B6- Dissociative disorders;535;22
L1-6B8- Feeding or eating disorders;536;22
L1-6C0- Elimination disorders;537;22
L1-6C2- Disorders of bodily distress or bodily experience;538;22
L1-6C7- Impulse control disorders;539;22
L1-6C9- Disruptive behaviour or dissocial disorders;540;22
L1-6D1- Personality disorders and related traits;541;22
L1-6D3- Paraphilic disorders;542;22
L1-6D5- Factitious disorders;543;22
L1-6D7- Neurocognitive disorders;544;22
L1-6E2- Mental or behavioural disorders associated with pregnancy, childbirth or the puerperium;545;22
L1-6E6- Secondary mental or behavioural syndromes associated with disorders or diseases classified elsewhere;546;22
L1-7A0- Insomnia disorders;547;25
L1-7A2- Hypersomnolence disorders;548;25
L1-7A4- Sleep-related breathing disorders;549;25
L1-7A6- Circadian rhythm sleep-wake disorders;550;25
L1-7A8- Sleep-related movement disorders;551;25
L1-7B0- Parasomnia disorders;552;25
L1-8A0- Movement disorders;553;13
L1-8A2- Disorders with neurocognitive impairment as a major feature;554;13
L1-8A4- Multiple sclerosis or other white matter disorders;555;13
L1-8A6- Epilepsy or seizures;556;13
L1-8A8- Headache disorders;557;13
L1-8B4- Spinal cord disorders excluding trauma;558;13
L1-8B6- Motor neuron diseases or related disorders;559;13
L1-8D2- Cerebral palsy;560;13
L1-8D4- Nutritional or toxic disorders of the nervous system;561;13
L1-8D6- Disorders of cerebrospinal fluid pressure or flow;562;13
L1-8D8- Disorders of autonomic nervous system;563;13
L1-8E0- Human prion diseases;564;13
L1-8E2- Disorders of consciousness;565;13
L1-8E4- Other disorders of the nervous system;566;13
L1-8E6- Postprocedural disorders of the nervous system;567;13
L1-9C2- Disorders of the eyeball affecting both anterior and posterior segments;568;16
L1-9C4- Disorders of the visual pathways or centres;569;16
L1-9C6- Glaucoma or glaucoma suspect;570;16
L1-9C8- Strabismus or ocular motility;571;16
L1-9D0- Disorders of refraction or accommodation;572;16
L1-9D2- Postprocedural disorders of eye or ocular adnexa;573;16
L1-9D4- Impairment of visual functions;574;16
L1-9D9- Vision impairment;575;16
L1-AB3- Diseases of inner ear;576;9
L1-AB5- Disorders with hearing impairment;577;9
L1-AB7- Disorders of ear, not elsewhere classified;578;9
L1-AB9- Postprocedural disorders of ear or mastoid process;579;9
L1-BA0- Hypertensive diseases;580;7
L1-BA2- Hypotension;581;7
L1-BA8- Diseases of coronary artery;582;7
L1-BB0- Pulmonary heart disease or diseases of pulmonary circulation;583;7
L1-BB2- Pericarditis;584;7
L1-BB4- Acute or subacute endocarditis;585;7
L1-BC4- Diseases of the myocardium or cardiac chambers;586;7
L1-BC6- Cardiac arrhythmia;587;7
L1-BD1 Heart Failure;588;7
L1-BD3- Diseases of arteries or arterioles;589;7
L1-BD7- Diseases of veins;590;7
L1-BD9- Disorders of lymphatic vessels or lymph nodes;591;7
L1-BE1- Postprocedural disorders of circulatory system;592;7
L1-CA0- Upper respiratory tract disorders;593;14
L1-CA2- Certain lower respiratory tract diseases;594;14
L1-CA4- Lung infections;595;14
L1-CA6- Lung diseases due to external agents;596;14
L1-CB0- Respiratory diseases principally affecting the lung interstitium;597;14
L1-CB2- Pleural, diaphragm or mediastinal disorders;598;14
L1-CB6- Postprocedural disorders of the respiratory system;599;14
L1-DA0- Diseases or disorders of orofacial complex;600;8
L1-DA2- Diseases of oesophagus;601;8
L1-DA9- Diseases of small intestine;602;8
L1-DB1- Diseases of appendix;603;8
L1-DB3- Diseases of large intestine;604;8
L1-DB9- Diseases of liver;605;8
L1-DC1- Diseases of gallbladder or biliary tract;606;8
L1-DC3- Diseases of pancreas;607;8
L1-DC5- Diseases of peritoneum;608;8
L1-DD3- Ischaemic vascular disorders of intestine;609;8
L1-DD5- Hernias;610;8
L1-DD7- Inflammatory bowel diseases;611;8
L1-DD9- Functional gastrointestinal disorders;612;8
L1-DE1- Postprocedural disorders of digestive system;613;8
L1-EB9- Metabolic and nutritional disorders affecting the skin;614;15
L1-EK7- Benign proliferations, neoplasms and cysts of the skin;615;15
L1-EK9- Disorders of the skin of uncertain or unpredictable malignant potential;616;15
L1-EL5- Postprocedural disorders of the skin;617;15
L1-FB8- Osteopathies or chondropathies;618;12
L1-GB2- Disorders of breast;619;10
L1-GC7- Postprocedural disorders of genitourinary system;620;10
L1-HA0- Sexual dysfunctions;621;4
L1-HA2- Sexual pain disorders;622;4
L1-HA6- Gender incongruence;623;4
L1-JA0- Abortive outcome of pregnancy;624;24
L1-JA2- Oedema, proteinuria, or hypertensive disorders in pregnancy, childbirth, or the puerperium;625;24
L1-JA4- Obstetric haemorrhage;626;24
L1-JA6- Certain specified maternal disorders predominantly related to pregnancy;627;24
L1-JA8- Maternal care related to the foetus, amniotic cavity or possible delivery problems;628;24
L1-JB0- Complications of labour or delivery;629;24
L1-JB2- Delivery;630;24
L1-JB4- Complications predominantly related to the puerperium;631;24
L1-JB6- Certain obstetric conditions, not elsewhere classified;632;24
L1-KA0- Foetus or newborn affected by maternal factors or by complications of pregnancy, labour or delivery;633;1
L1-KA2- Disorders of newborn related to length of gestation or foetal growth;634;1
L1-KA4- Birth injury;635;1
L1-KA6- Infections of the foetus or newborn;636;1
L1-KA8- Haemorrhagic or haematological disorders of foetus or newborn;637;1
L1-KB0- Neurological disorders specific to the perinatal or neonatal period;638;1
L1-KB2- Respiratory disorders specific to the perinatal or neonatal period;639;1
L1-KB4- Cardiovascular disorders present in the perinatal or neonatal period;640;1
L1-KB6- Transitory endocrine or metabolic disorders specific to foetus or newborn;641;1
L1-KB8- Digestive system disorders of foetus or newborn;642;1
L1-KC0- Genitourinary system disorders specific to the perinatal or neonatal period;643;1
L1-KC2- Disorders involving the integument of foetus or newborn;644;1
L1-KD1- Disturbances of temperature regulation of newborn;645;1
L1-KD3- Certain disorders originating in the perinatal period;646;1
L1-LD2- Multiple developmental anomalies or syndromes;647;5
L1-LD4- Chromosomal anomalies, excluding gene mutations;648;5
L1-MB2- Mental or behavioural symptoms, signs or clinical findings;649;28
L1-MH1- Ill-defined and unknown causes of mortality;650;28
L1-NA0- Injuries to the head;651;21
L1-NA2- Injuries to the neck;652;21
L1-NA8- Injuries to the thorax;653;21
L1-NB5- Injuries to the abdomen, lower back, lumbar spine or pelvis;654;21
L1-NC1- Injuries to the shoulder or upper arm;655;21
L1-NC3- Injuries to the elbow or forearm;656;21
L1-NC5- Injuries to the wrist or hand;657;21
L1-NC7- Injuries to the hip or thigh;658;21
L1-NC9- Injuries to the knee or lower leg;659;21
L1-ND1- Injuries to the ankle or foot;660;21
L1-ND3- Injuries involving multiple body regions;661;21
L1-ND5- Injuries to unspecified part of trunk, limb or body region;662;21
L1-ND7- Effects of foreign body entering through natural orifice;663;21
L1-NE4- Frostbite;664;21
L1-NE6- Harmful effects of substances;665;21
L1-NE8- Injury or harm arising from surgical or medical care, not elsewhere classified;666;21
L1-NF0- Other or unspecified effects of external causes;667;21
L1-PJ0- Exposure to extreme forces of nature;668;19
L1-PJ2- Maltreatment;669;19
L1-PJ4- Legal intervention;670;19
L1-RA0- International provisional assignment of new diseases of uncertain aetiology;671;3
L1-RA2- National provisional assignment of new diseases of uncertain aetiology;672;3
L1-VA9- Brief Model Disability Survey;673;27
L2-1A0- - Bacterial intestinal infections;674;2
L2-1A1- - Bacterial foodborne intoxications;675;2
L2-1A2- - Viral intestinal infections;676;2
L2-1A3- - Protozoal intestinal infections;677;2
L2-1A6- - Syphilis;678;2
L2-1A7- - Gonococcal infection;679;2
L2-1A8- - Sexually transmissible infections due to chlamydia;680;2
L2-1B1- - Tuberculosis;681;2
L2-1B4- - Acute rheumatic fever;682;2
L2-1C2- - Other diseases due to chlamydiae;683;2
L2-1C3- - Rickettsioses;684;2
L2-1D9- - Viral infection of unspecified site;685;2
L2-1E7- - Infections due to poxvirus;686;2
L2-1E8- - Human papillomavirus infection of skin or mucous membrane;687;2
L2-1E9- - Varicella zoster virus infections;688;2
L2-1F4- - Malaria;689;2
L2-1F5- - Nonintestinal protozoal diseases;690;2
L2-1F6- - Helminthiases;691;2
L2-1G0- - Infestations by ectoparasites;692;2
L2-2A2- - Myeloproliferative neoplasms;693;23
L2-2A3- - Myelodysplastic syndromes;694;23
L2-2A4- - Myelodysplastic and myeloproliferative neoplasms;695;23
L2-2A5- - Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1;696;23
L2-2A7- - Precursor lymphoid neoplasms;697;23
L2-2A8- - Mature B-cell neoplasms;698;23
L2-2A9- - Mature T-cell or NK-cell neoplasms;699;23
L2-2B5- - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues;700;23
L2-2D4- - Malignant neoplasms of ill-defined or unspecified primary sites;701;23
L2-2D5- - Malignant neoplasm metastases;702;23
L2-2E8- - Benign mesenchymal neoplasms;703;23
L2-2E9- - Benign non-mesenchymal neoplasms;704;23
L2-3A0- - Nutritional or metabolic anaemias;705;6
L2-3A1- - Haemolytic anaemias;706;6
L2-3A6- - Pure red cell aplasia;707;6
L2-3A8- - Polycythaemia;708;6
L2-3B1- - Coagulation defects;709;6
L2-3B5- - Fibrinolytic defects;710;6
L2-5A0- - Disorders of the thyroid gland or thyroid hormones system;711;17
L2-5A1- - Diabetes mellitus;712;17
L2-5A4- - Other disorders of glucose regulation or pancreatic internal secretion;713;17
L2-5A5- - Disorders of the parathyroids or parathyroid hormone system;714;17
L2-5A6- - Disorders of the pituitary hormone system;715;17
L2-5A7- - Disorders of the adrenal glands or adrenal hormone system;716;17
L2-5A8- - Disorders of the gonadal hormone system;717;17
L2-5A9- - Certain disorders of puberty;718;17
L2-5B0- - Polyglandular dysfunction;719;17
L2-5B1- - Endocrine disorders, not elsewhere classified;720;17
L2-5B5- - Undernutrition;721;17
L2-5B8- - Overweight, obesity or specific nutrient excesses;722;17
L2-5C5- - Inborn errors of metabolism;723;17
L2-5C6- - Disorders of metabolite absorption or transport;724;17
L2-5C7- - Disorders of fluid, electrolyte or acid-base balance;725;17
L2-5C8- - Disorders of lipoprotein metabolism or certain specified lipidaemias;726;17
L2-5D0- - Other metabolic disorders;727;17
L2-6A6- - Bipolar or related disorders;728;22
L2-6A7- - Depressive disorders;729;22
L2-6C4- - Disorders due to substance use;730;22
L2-6C5- - Disorders due to addictive behaviours;731;22
L2-6D8- - Dementia;732;22
L2-8B0- - Intracranial haemorrhage;733;13
L2-8B1- - Cerebral ischaemia;734;13
L2-8B8- - Disorders of cranial nerves;735;13
L2-8B9- - Nerve root or plexus disorders;736;13
L2-8C0- - Polyneuropathy;737;13
L2-8C1- - Mononeuropathy;738;13
L2-8C2- - Hereditary neuropathy;739;13
L2-8C6- - Myasthenia gravis or certain specified neuromuscular junction disorders;740;13
L2-8C7- - Primary disorders of muscles;741;13
L2-8C8- - Secondary myopathies;742;13
L2-9A0- - Disorders of eyelid or peri-ocular area;743;16
L2-9A1- - Disorders of lacrimal apparatus;744;16
L2-9A2- - Disorders of orbit;745;16
L2-9A6- - Disorders of conjunctiva;746;16
L2-9A7- - Disorders of the cornea;747;16
L2-9A8- - Disorders of the anterior chamber;748;16
L2-9A9- - Disorders of the anterior uvea;749;16
L2-9B0- - Functional disorders of the pupil;750;16
L2-9B1- - Disorders of lens;751;16
L2-9B5- - Disorders of sclera;752;16
L2-9B6- - Disorders of the choroid;753;16
L2-9B7- - Disorders of the retina;754;16
L2-9B8- - Disorders of the vitreous body;755;16
L2-9D5- - Subjective visual experiences;756;16
L2-AA0- - Otitis externa;757;9
L2-AA4- - Noninflammatory disorders of the external ear;758;9
L2-AA8- - Otitis media;759;9
L2-BA4- - Acute ischaemic heart disease;760;7
L2-BA5- - Chronic ischaemic heart disease;761;7
L2-BB6- - Mitral valve disease;762;7
L2-BB7- - Aortic valve disease;763;7
L2-BB8- - Tricuspid valve disease;764;7
L2-BB9- - Pulmonary valve disease;765;7
L2-BC7 Cardiac arrhythmia;766;7
L2-BC8 Cardiac arrhythmia;767;7
L2-BD4- - Chronic arterial occlusive disease;768;7
L2-CA7- - Pneumonitis;769;14
L2-DA4- - Diseases of stomach;770;8
L2-DA5- - Diseases of duodenum;771;8
L2-DA6- - Ulcer of stomach or duodenum;772;8
L2-DB5- - Acquired anatomical alterations of the anal canal;773;8
L2-DB6- - Haemorrhoids or perianal venous conditions;774;8
L2-DC7- - Diverticular disease of small intestine;775;8
L2-DC8- - Diverticular disease of large intestine;776;8
L2-DC9- - Diverticular disease of intestine of overlapping sites;777;8
L2-DD0- - Diverticular disease of unspecified part of intestine;778;8
L2-EA0- - - Viral exanthems;779;15
L2-EA4- - Certain skin disorders attributable to bacterial infection;780;15
L2-EA8- - Dermatitis and eczema;781;15
L2-EA9- - Papulosquamous dermatoses;782;15
L2-EB0- - Urticaria, angioedema and other urticarial disorders;783;15
L2-EB1- - Inflammatory erythemas and other reactive inflammatory dermatoses;784;15
L2-EB4- - Immunobullous diseases of the skin;785;15
L2-EB5- - Cutaneous lupus erythematosus;786;15
L2-EB6- - Scarring or sclerosing inflammatory dermatoses;787;15
L2-EC1- - Genetic syndromes affecting the skin;788;15
L2-EC3- - Genetically-determined epidermolysis bullosa;789;15
L2-EC4- - Genetic disorders affecting dermal collagen, elastin or other matrix proteins;790;15
L2-EC5- - Specified developmental anomalies affecting the skin;791;15
L2-EC9- - Disturbances of cutaneous sensation;792;15
L2-ED0- - Psychological or psychiatric conditions affecting the skin;793;15
L2-ED3- - Neurological conditions affecting the skin;794;15
L2-ED5- - Disorders of the epidermis and epidermal appendages;795;15
L2-EF2- - Disorders of cutaneous blood and lymphatic vessels;796;15
L2-EG3- - Skin disorders involving the head and neck;797;15
L2-EG6- - Skin disorders involving the genital and perianal regions;798;15
L2-EH1- - Skin disorders specific to the perinatal or neonatal period;799;15
L2-EH6- - Drug eruptions;800;15
L2-EH9- - Dermatoses provoked by physical or environmental factors;801;15
L2-EK0- - Dermatitis due to exogenous factors;802;15
L2-EK1- - Allergy to substances in contact with the skin;803;15
L2-EK2- - Dermatoses provoked by contact with irritant or noxious substance;804;15
L2-EL1- - Cutaneous markers of internal malignancy;805;15
L2-EL6- - Adverse cutaneous effects of therapeutic ionizing irradiation;806;15
L2-EL7- - Complications of cutaneous cosmetic procedures;807;15
L2-FA0- - Osteoarthritis;808;12
L2-FA1- - Infection related arthropathies;809;12
L2-FA2- - Inflammatory arthropathies;810;12
L2-FA3- - Certain specified joint disorders or deformities of limbs;811;12
L2-FA7- - Structural disorders of spine;812;12
L2-FA8- - Degenerative condition of spine;813;12
L2-FA9- - Inflammation of spine;814;12
L2-FB0- - Spondylopathies;815;12
L2-FB3- - Disorders of muscles;816;12
L2-FB4- - Disorders of synovium or tendon;817;12
L2-FB5- - Miscellaneous specified soft tissue disorders;818;12
L2-GA0- - Inflammatory disorders of the female genital tract;819;10
L2-GA1- - Noninflammatory disorders of female genital tract;820;10
L2-GA2- - Abnormal uterine or vaginal bleeding;821;10
L2-GA4- - Dermatoses of female genitalia;822;10
L2-GA8- - Dermatoses of male genitalia;823;10
L2-GA9- - Diseases of prostate;824;10
L2-GB4- - Glomerular diseases;825;10
L2-GB5- - Renal tubulo-interstitial diseases;826;10
L2-GB6- - Kidney failure;827;10
L2-GB7- - Urolithiasis;828;10
L2-GB8- - Cystic or dysplastic kidney disease;829;10
L2-GC0- - Certain specified diseases of urinary system;830;10
L2-GC4- - Female pelvic floor dysfunction;831;10
L2-KC3- - Skin disorders associated with prematurity;832;1
L2-KC5- - Iatrogenic injuries involving the skin of the neonate;833;1
L2-LA0- - Structural developmental anomalies of the nervous system;834;5
L2-LA1- - Structural developmental anomalies of the eye, eyelid or lacrimal apparatus;835;5
L2-LA2- - Structural developmental anomalies of the ear;836;5
L2-LA3- - Structural developmental anomalies of the face, mouth or teeth;837;5
L2-LA6- - Structural developmental anomalies of the neck;838;5
L2-LA7- - Structural developmental anomalies of the respiratory system;839;5
L2-LA8- - Structural developmental anomalies of the circulatory system;840;5
L2-LB0- - Structural developmental anomalies of the diaphragm, abdominal wall or umbilical cord;841;5
L2-LB1- - Structural developmental anomalies of the digestive tract;842;5
L2-LB2- - Structural developmental anomalies of the liver, biliary tract, pancreas or spleen;843;5
L2-LB3- - Structural developmental anomalies of the urinary system;844;5
L2-LB4- - Structural developmental anomalies of the female genital system;845;5
L2-LB5- - Structural developmental anomalies of the male genital system;846;5
L2-LB6- - Structural developmental anomalies of the breast;847;5
L2-LB7- - Structural developmental anomalies of the skeleton;848;5
L2-LC0- - Structural developmental anomalies of the skin;849;5
L2-LC8- - Structural developmental anomalies of the adrenal glands;850;5
L2-LD5- - Sex chromosome anomalies;851;5
L2-MA0- - Symptoms of blood, blood-forming organs, or the immune system;852;28
L2-MA1- - Clinical findings in blood, blood-forming organs, or the immune system;853;28
L2-MA5- - Results of function studies of the endocrine, nutritional or metabolic diseases;854;28
L2-MA8- - Symptoms or signs involving speech or voice;855;28
L2-MB4- - Symptoms or signs involving the nervous system;856;28
L2-MB7- - Clinical findings in the nervous system;857;28
L2-MC1- - Symptoms or signs involving the visual system;858;28
L2-MC4- - Symptoms or signs involving the ear or mastoid process;859;28
L2-MC8- - Symptoms or signs involving the circulatory system;860;28
L2-MD1- - Symptoms or signs involving the respiratory system;861;28
L2-MD4- - Clinical findings in the respiratory system;862;28
L2-MD8- - Symptoms or signs involving the digestive system or abdomen;863;28
L2-ME2- - Clinical findings in the digestive system;864;28
L2-ME6- - Symptom or signs involving the skin;865;28
L2-ME8- - Symptoms or signs of the musculoskeletal system;866;28
L2-ME9- - Clinical findings in the musculoskeletal system;867;28
L2-MF3- - Symptoms, signs or clinical findings involving the female genital system;868;28
L2-MF4- - Symptoms, signs or clinical findings involving the male genital system;869;28
L2-MF5- - Symptoms, signs or clinical findings involving the urinary system;870;28
L2-MF6- - Clinical findings in specimens from female genital organs;871;28
L2-MF7- - Clinical findings in specimens from male genital organs;872;28
L2-MF8- - Clinical findings in specimens from the urinary system;873;28
L2-MF9- - Clinical findings on examination of urine, without diagnosis;874;28
L2-MG2- - General symptoms;875;28
L2-MG5- - Finding of microorganism resistant to antimicrobial drugs;876;28
L2-MG6- - Clinical findings in specimens from other specified organs, systems and tissues;877;28
L2-MG7- - Abnormal results, not elsewhere classified;878;28
L2-NA3- - Injury of nerves or spinal cord at neck level;879;21
L2-NA9- - Injury of nerves or spinal cord at thorax level;880;21
L2-NB6- - Injury of nerves or lumbar spinal cord at abdomen, lower back or pelvis level;881;21
L2-ND9- - Burns of external body surface, specified by site;882;21
L2-NE0- - Burns of eye or internal organs;883;21
L2-NE1- - Burns of multiple or unspecified body regions;884;21
L2-PA0- - Unintentional transport injury event;885;19
L2-PA6- - Unintentional fall;886;19
L2-PA7- - Unintentional contact with person, animal or plant;887;19
L2-PA8- - Unintentional exposure to object, not elsewhere classified;888;19
L2-PA9- - Unintentional immersion, submersion or falling into water;889;19
L2-PB0- - Unintentional threat to breathing;890;19
L2-PB1- - Unintentional exposure to thermal mechanism;891;19
L2-PB2- - Unintentional exposure to or harmful effects of substances;892;19
L2-PB5- - Unintentional exposure to other mechanism;893;19
L2-PB8- - Intentional self-harm by transport injury event;894;19
L2-PC3- - Intentional self-harm by fall or jump;895;19
L2-PC4- - Intentional self-harm by contact with person, animal or plant;896;19
L2-PC5- - Intentional self-harm by exposure to object, not elsewhere classified;897;19
L2-PC6- - Intentional self-harm by immersion, submersion or falling into water;898;19
L2-PC7- - Intentional self-harm by threat to breathing;899;19
L2-PC8- - Intentional self-harm by exposure to thermal mechanism;900;19
L2-PC9- - Intentional self-harm by exposure to or harmful effects of substances;901;19
L2-PD2- - Intentional self-harm by exposure to other mechanism;902;19
L2-PD5- - Assault by transport events;903;19
L2-PE0- - Assault by causing a fall or jump;904;19
L2-PE1- - Assault by contact with person, animal or plant;905;19
L2-PE2- - Assault by exposure to object not elsewhere classified;906;19
L2-PE5- - Assault by immersion, submersion or falling into water;907;19
L2-PE6- - Assault by threat to breathing;908;19
L2-PE7- - Assault by exposure to thermal mechanism;909;19
L2-PE8- - Assault by exposure to or harmful effects of substances;910;19
L2-PF1- - Assault by exposure to other mechanism;911;19
L2-PF4- - Transport injury event of undetermined intent;912;19
L2-PG5- - Fall or jump with undetermined intent;913;19
L2-PG6- - Contact with person, animal or plant with undetermined intent;914;19
L2-PG7- - Contact with object, not elewhere classified with undetermined intent;915;19
L2-PH1- - Immersion, submersion or falling into water with undetermined intent;916;19
L2-PH2- - Threat to breathing with undetermined intent;917;19
L2-PH3- - Exposure to thermal mechanism with undetermined intent;918;19
L2-PH4- - Exposure to or harmful effects of substances, undetermined intent;919;19
L2-PH7- - Exposure to other mechanism with undetermined intent;920;19
L2-PJ6- - Explosion of marine weapons during armed conflict;921;19
L2-PJ7- - Attack on or destruction of aircraft during armed conflict;922;19
L2-PJ8- - Other explosions or fragments during armed conflict;923;19
L2-PJ9- - Fires, conflagrations or hot substances during armed conflict;924;19
L2-PK0- - Firearm discharge or other forms of conventional warfare during armed conflict;925;19
L2-PK1- - Use of nuclear weapons during armed conflict;926;19
L2-PK2- - Use of biological weapons during armed conflict;927;19
L2-PK3- - Chemical weapons or other forms of unconventional warfare during armed conflict;928;19
L2-PK4- - Injury event occurring after cessation of armed conflict;929;19
L2-PK8- - Surgical or other medical procedures associated with injury or harm in diagnostic or therapeutic use;930;19
L2-PK9- - Surgical or other medical devices, implants or grafts associated with injury or harm in therapeutic use;931;19
L2-PL0- - Substances associated with injury or harm in therapeutic use;932;19
L2-QA0- - Contact with health services for purposes of examination or investigation;933;20
L2-QA1- - Contact with health services for counselling;934;20
L2-QA2- - Contact with health services for reasons associated with reproduction;935;20
L2-QA5- - Health care related circumstances influencing the episode of care without injury or harm;936;20
L2-QB1- - Factors related to medical facilities and other health care;937;20
L2-QB2- - Donors of organs or tissues;938;20
L2-QB3- - Fitting, adjustment or management of devices;939;20
L2-QB4- - Dependence on enabling machines or devices;940;20
L2-QB5- - Presence of device, implants or grafts;941;20
L2-QB6- - Surgical or postsurgical states;942;20
L2-QB7- - Convalescence;943;20
L2-QB8- - Contact with health services for specific surgical interventions;944;20
L2-QB9- - Contact with health services for nonsurgical interventions not involving devices;945;20
L2-QC0- - Contact with health services related to immunizations or certain other prophylactic measures;946;20
L2-QC1- - Interventions not carried out;947;20
L2-QC2- - Contact with health services associated with the health of others;948;20
L2-QC4- - Personal or family history or late effect of prior health problems;949;20
L2-QC9- - Risk factors associated with infectious or certain other conditions;950;20
L2-QD3- - Concern about body appearance;951;20
L2-QD5- - Problems associated with finances;952;20
L2-QD6- - Problems associated with drinking water or nutrition;953;20
L2-QD7- - Problems associated with the environment;954;20
L2-QD8- - Problems associated with employment or unemployment;955;20
L2-QD9- - Problems associated with education;956;20
L2-QE0- - Problems associated with social or cultural environment;957;20
L2-QE1- - Problems associated with health behaviours;958;20
L2-QE3- - Problems associated with social insurance or welfare;959;20
L2-QE4- - Problems associated with the justice system;960;20
L2-QE5- - Problems associated with relationships;961;20
L2-QE6- - Problems associated with absence, loss or death of others;962;20
L2-QE8- - Problems associated with harmful or traumatic events;963;20
L2-QE9- - Problems associated with upbringing;964;20
L2-QF0- - Acquired absence of body structure;965;20
L2-QF2- - Difficulty or need for assistance with activities;966;20
L2-SA0- - Organ system disorders (TM1);967;26
L2-SB3- - Other body system disorders (TM1);968;26
L2-SD7- - Qi, blood and fluid disorders (TM1);969;26
L2-SD8- - Mental and emotional disorders (TM1);970;26
L2-SD9- - External contraction disorders (TM1);971;26
L2-SE3- - Childhood and adolescence associated disorders (TM1);972;26
L2-SE7- - Principle-based patterns (TM1);973;26
L2-SE8- - Environmental factor patterns (TM1);974;26
L2-SE9- - Body constituents patterns (TM1);975;26
L2-SF5- - Organ system patterns (TM1);976;26
L2-SG2- - Meridian and collateral patterns (TM1);977;26
L2-SG6- - Six stage patterns (TM1);978;26
L2-SG7- - Triple energizer stage patterns (TM1);979;26
L2-SG8- - Four phase patterns (TM1);980;26
L2-SH4- - Four constitution medicine patterns (TM1);981;26
L2-VA0- - Cognition;982;27
L2-VA1- - Mobility;983;27
L2-VA2- - Self-care WHODAS;984;27
L2-VA3- - Getting along;985;27
L2-VA4- - Life activities;986;27
L2-VA5- - Participation and impact of health problems;987;27
L2-VB0- - Mental functions;988;27
L2-VB1- - Sensory functions and pain;989;27
L2-VB6- - Voice and speech functions;990;27
L2-VB7- - Functions of the cardiovascular, haematological, immunological and respiratory systems;991;27
L2-VB8- - Functions of the digestive, metabolic and endocrine systems;992;27
L2-VB9- - Genitourinary and reproductive functions;993;27
L2-VC0- - Neuromusculoskeletal and movement-related functions;994;27
L2-VC1- - General tasks and demands;995;27
L2-VC2- - Mobility;996;27
L2-VC3- - Self-care;997;27
L2-VC4- - Domestic life;998;27
L2-VC5- - Interpersonal interactions and relationships;999;27
L3-1F6- - - Diseases due to nematodes;1000;2
L3-1F7- - - Diseases due to cestodes;1001;2
L3-1F8- - - Diseases due to trematodes;1002;2
L3-2B0- - - Mature T-cell or NK-cell lymphoma, primary cutaneous specified types;1003;23
L3-2B5- - - Malignant mesenchymal neoplasms;1004;23
L3-2B6- - - Malignant neoplasms of lip, oral cavity or pharynx;1005;23
L3-2B7- - - Malignant neoplasms of digestive organs;1006;23
L3-2C2- - - Malignant neoplasms of middle ear, respiratory or intrathoracic organs;1007;23
L3-2C3- - - Malignant neoplasms of skin;1008;23
L3-2C4- - - Malignant neoplasms of peripheral nerves or autonomic nervous system;1009;23
L3-2C5- - - Malignant neoplasms of retroperitoneum, peritoneum or omentum;1010;23
L3-2C6- - - Malignant neoplasms of breast;1011;23
L3-2C7- - - Malignant neoplasms of female genital organs;1012;23
L3-2C8- - - Malignant neoplasms of male genital organs;1013;23
L3-2C9- - - Malignant neoplasms of urinary tract;1014;23
L3-2D0- - - Malignant neoplasms of eye or ocular adnexa;1015;23
L3-2D1- - - Malignant neoplasms of endocrine glands;1016;23
L3-2D6- - - Malignant neoplasm metastasis in lymph nodes;1017;23
L3-2D7- - - Malignant neoplasm metastasis in thoracic or respiratory organs;1018;23
L3-2D8- - - Malignant neoplasm metastasis in digestive system;1019;23
L3-2D9- - - Malignant neoplasm metastasis in retroperitoneum or peritoneum;1020;23
L3-2E0- - - Malignant neoplasm metastasis in other sites;1021;23
L3-2F0- - - Benign neoplasm of respiratory or intrathoracic organs;1022;23
L3-2F2- - - Benign cutaneous neoplasms;1023;23
L3-3A1- - - Congenital haemolytic anaemia;1024;6
L3-3A2- - - Acquired haemolytic anaemia;1025;6
L3-3B1- - - Congenital or constitutional haemorrhagic condition;1026;6
L3-3B2- - - Haemorrhagic diseases due to acquired coagulation factor defects;1027;6
L3-5A2- - - Acute complications of diabetes mellitus;1028;17
L3-5B6- - - Sequelae of malnutrition and certain specified nutritional deficiencies;1029;17
L3-5B8- - - Overweight or obesity;1030;17
L3-5B9- - - Certain specified nutrient excesses;1031;17
L3-AA0- - - Infectious diseases of external ear;1032;9
L3-AA1- - - Noninfectious inflammation of external ear;1033;9
L3-AA8- - - Nonsuppurative otitis media;1034;9
L3-AA9- - - Suppurative otitis media;1035;9
L3-EA0- - - Viral exanthems;1036;15
L3-EA1- - - Certain dermatoses with suspected viral aetiology;1037;15
L3-EA2- - - Dermatoses from distant or systemic viral infection;1038;15
L3-EA4- - - Predominantly tropical or subtropical bacterial infections affecting skin;1039;15
L3-EB2- - - Neutrophilic dermatoses;1040;15
L3-ED0- - - Self-inflicted skin disorders;1041;15
L3-ED5- - - Disorders of epidermal keratinisation;1042;15
L3-ED6- - - Disorders of skin colour;1043;15
L3-ED7- - - Disorders of hair;1044;15
L3-ED8- - - Disorders of the hair follicle;1045;15
L3-EE0- - - Disorders of eccrine sweat glands or sweating;1046;15
L3-EE1- - - Disorders of the nail or perionychium;1047;15
L3-EE2- - - Disorders of epidermal integrity;1048;15
L3-EE4- - - Disorders of cutaneous connective tissue;1049;15
L3-EE8- - - Histiocytic-granulomatous disorders of the skin;1050;15
L3-EE9- - - Benign dermal lymphocytic or lymphoplasmacytic infiltrations or proliferations;1051;15
L3-EF0- - - Disorders of subcutaneous fat;1052;15
L3-EF2- - - Malformations involving cutaneous blood vessels;1053;15
L3-EF3- - - Purpura or bruising;1054;15
L3-EF5- - - Dermatoses attributable to hyperviscosity or microvascular occlusion;1055;15
L3-EF6- - - Dermatoses resulting from vascular insufficiency;1056;15
L3-EG0- - - Functional vascular disorders of the skin;1057;15
L3-EG4- - - Disorders of the external ear involving the skin;1058;15
L3-EG6- - - Dermatoses of the anus, perianal area or perineum;1059;15
L3-EH1- - - Neonatal skin infection;1060;15
L3-EJ1- - - Dermatoses provoked by heat or electricity;1061;15
L3-EJ2- - - Dermatoses provoked by light or UV radiation;1062;15
L3-EJ7- - - Dermatoses due to ionizing radiation;1063;15
L3-EK2- - - Phototoxic reactions to skin contact with photoactive agents;1064;15
L3-KC5- - - Postnatal iatrogenic skin injury;1065;1
L3-LA4- - - Clefts of lip, alveolus or palate;1066;5
L3-LA8- - - Structural developmental anomaly of heart or great vessels;1067;5
L3-LB8- - - Congenital deformities of fingers or toes;1068;5
L3-LC0- - - Developmental hamartomata of the epidermis and epidermal appendages;1069;5
L3-LC2- - - Hamartomata derived from dermal connective tissue;1070;5
L3-LC3- - - Developmental defects of hair or nails;1071;5
L3-LC5- - - Developmental anomalies of cutaneous vasculature;1072;5
L3-LC6- - - Congenital anomalies of skin development;1073;5
L3-MB5- - - Paralytic symptoms;1074;28
L3-MD2- - - Haemorrhage from respiratory passages;1075;28
L3-MD9- - - Symptoms related to the upper gastrointestinal tract;1076;28
L3-ME0- - - Symptoms related to the lower gastrointestinal tract or abdomen;1077;28
L3-MG3- - - Pain;1078;28
L3-NA3- - - Injury of spinal cord at neck level;1079;21
L3-NA4- - - Injury of nerves at neck level;1080;21
L3-NA9- - - Injury of spinal cord at thorax level;1081;21
L3-NB0- - - Injury of nerves at thorax level;1082;21
L3-NB6- - - Injury of spinal cord at abdomen, lower back or pelvis level;1083;21
L3-NB7- - - Injury of nerves at abdomen, lower back or pelvis level;1084;21
L3-PA0- - - Unintentional land transport road traffic injury event;1085;19
L3-PA1- - - Unintentional land transport off-road nontraffic injury event;1086;19
L3-PA2- - - Unintentional land transport injury event unknown whether road traffic or off-road nontraffic;1087;19
L3-PA3- - - Unintentional railway transport injury event;1088;19
L3-PA4- - - Unintentional water transport injury event;1089;19
L3-PB2- - - Unintentional exposure to or harmful effects of drugs, medicaments or biological substances;1090;19
L3-PB3- - - Unintentional exposure to or harmful effects of substances chiefly nonmedicinal as to source;1091;19
L3-PB9- - - Intentional self-harm by water transport injury event;1092;19
L3-PC0- - - Intentional self-harm by air or space transport injury event;1093;19
L3-PC9- - - Intentional self-harm by exposure to or harmful effects of drugs, medicaments or biological substances;1094;19
L3-PD0- - - Intentional self-harm by exposure to or harmful effects of substances chiefly nonmedicinal as to source;1095;19
L3-PD6- - - Assault by water transport injury event;1096;19
L3-PD7- - - Assault by air or space transport injury event;1097;19
L3-PE3- - - Assault by being cut or pierced by sharp object;1098;19
L3-PE8- - - Assault by exposure to or harmful effects of drugs, medicaments or biological substances;1099;19
L3-PE9- - - Assault by exposure to or harmful effects of substances chiefly nonmedicinal as to source;1100;19
L3-PF4- - - Land transport road traffic injury event of undetermined intent;1101;19
L3-PF5- - - Land transport off-road nontraffic injury event of undetermined intent;1102;19
L3-PF6- - - Land transport injury event of undetermined intent, unknown whether road traffic or off-road nontraffic;1103;19
L3-PF7- - - Railway transport injury event of undetermined intent;1104;19
L3-PF8- - - Water transport injury event of undetermined intent;1105;19
L3-PG2- - - Air or space transport injury event of undetermined intent;1106;19
L3-PG7- - - Struck by projectile from firearm of undetermined intent;1107;19
L3-PG9- - - Cut or pierced by sharp object of undetermined intent;1108;19
L3-PH4- - - Exposure to or harmful effects of undetermined intent of drugs, medicaments or biological substances;1109;19
L3-PH5- - - Exposure to or harmful effects of undetermined intent of substances chiefly nonmedicinal as to source;1110;19
L3-QA3- - - Contact with health services for procreative management;1111;20
L3-QA5- - - Circumstances associated with a surgical or other medical procedure influencing the episode of care, without injury or harm;1112;20
L3-QA6- - - Circumstances associated with a surgical or other medical device influencing the episode of care without injury or harm;1113;20
L3-QA7- - - Circumstances associated with exposure to a drug, medicament or biological substance influencing the episode of care without injury or harm;1114;20
L3-QA8- - - Circumstances associated with other aspects of care influencing the episode of care without injury or harm;1115;20
L3-QC4- - - Personal history of health problems;1116;20
L3-QC6- - - Family history of health problems;1117;20
L3-QD0- - - Carrier of infectious disease agent;1118;20
L3-QE1- - - Hazardous substance use;1119;20
L3-SA0- - - Liver system disorders (TM1);1120;26
L3-SA1- - - Heart system disorders (TM1);1121;26
L3-SA5- - - Spleen system disorders (TM1);1122;26
L3-SA6- - - Lung system disorders (TM1);1123;26
L3-SA9- - - Kidney system disorders (TM1);1124;26
L3-SB3- - - Skin and mucosa system disorders (TM1);1125;26
L3-SB8- - - Female reproductive system disorders (TM1) (including childbirth);1126;26
L3-SC5- - - Bone, joint and muscle system disorders (TM1);1127;26
L3-SC7- - - Eye, ear, nose and throat system disorders (TM1);1128;26
L3-SD0- - - Brain system disorders (TM1);1129;26
L3-SE0- - - Warmth disorders (TM1);1130;26
L3-SE9- - - Qi patterns (TM1);1131;26
L3-SF0- - - Blood patterns (TM1);1132;26
L3-SF1- - - Fluid patterns (TM1);1133;26
L3-SF2- - - Essence patterns (TM1);1134;26
L3-SF5- - - Liver system patterns (TM1);1135;26
L3-SF6- - - Heart system patterns (TM1);1136;26
L3-SF7- - - Spleen system patterns (TM1);1137;26
L3-SF8- - - Lung system patterns (TM1);1138;26
L3-SF9- - - Kidney system patterns (TM1);1139;26
L3-SG2- - - Main Meridian Patterns (TM1);1140;26
L3-SG3- - - Extra Meridian Patterns (TM1);1141;26
L3-SG8- - - Defense phase patterns (TM1);1142;26
L3-SG9- - - Qi phase patterns (TM1);1143;26
L3-SH0- - - Nutrient phase patterns (TM1);1144;26
L3-SH1- - - Blood phase patterns (TM1);1145;26
L3-SH4- - - Large yang type patterns (TM1);1146;26
L3-SH5- - - Small yang type patterns (TM1);1147;26
L3-SH6- - - Large yin type patterns (TM1);1148;26
L3-SH7- - - Small yin type patterns(TM1);1149;26
L4-2B8- - - - Malignant neoplasms of intestine;1150;23
L4-ED8- - - - Acne and related disorders;1151;15
L4-EE5- - - - Poikiloderma;1152;15
L4-EE6- - - - Fibromatoses and keloids;1153;15
L4-EF7- - - - Dermatoses due to venous disease;1154;15
L4-EG4- - - - Inflammatory disorders of the external ear;1155;15
L4-EJ2- - - - Chronic effects of ultraviolet radiation on the skin;1156;15
L4-EJ4- - - - Acute effects of ultraviolet radiation on normal skin;1157;15
L4-PF8- - - - Water transport injury event of undetermined intent with water vessel damaged, disabled or destroyed;1158;19
L4-PF9- - - - Water transport injury event of undetermined intent with water vessel not damaged, disabled or destroyed;1159;19
L4-SA1- - - - Palpitation disorders (TM1);1160;26
L4-SA2- - - - Chest impediment disorders (TM1);1161;26
L4-SA7- - - - Cough disorders (TM1);1162;26
L4-SA9- - - - Strangury disorders (TM1);1163;26
L4-SB4- - - - Furuncle disorders (TM1);1164;26
L4-SB6- - - - Abscess disorders (TM1);1165;26
L4-SB8- - - - Menstruation associated disorders (TM1);1166;26
L4-SC0- - - - Pregnancy associated disorders (TM1);1167;26
L4-SC1- - - - Puerperium associated disorders (TM1);1168;26
L4-SC2- - - - Other female reproductive system associated disorders (TM1);1169;26
L4-SC5- - - - Joint impediment disorders (TM1);1170;26
L4-SC8- - - - Deafness disorders (TM1);1171;26
L4-SD1- - - - Headache disorders (TM1);1172;26
L4-SD3- - - - Wind stroke disorders (TM1);1173;26
L5-2B9- - - - - Malignant neoplasms of large intestine;1174;23
L5-SB8- - - - - Menstruation cycle disorders (TM1);1175;26
